CureVac: Final Analysis of Pivotal Phase 2b/3 HERALD Study

July 1, 2021
Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
Franz-Werner Haas  
Chief Executive Officer  

Ulrike Gnad-Vogt  
Interim Chief Development Officer  

Mariola Fotin-Mleczek  
Chief Technology Officer  

Pierre Kemula  
Chief Financial Officer
The HERALD Study: Key Data from Final Analysis

204 sequenced, adjudicated cases

Original strain

Alpha (B.1.1.7)

B.1.621 (Colombia)

Gamma (P.1)

Lambda (C.37)

Delta (B.1.617.2)

Other

~51% Variants of Concern

~35% Variants of Interest

~11% Less explored variants

~3% Wild type strain

15 COVID-19 STRAINS

48% Efficacy of CVnCoV in the prevention of COVID-19 cases of any severity

228 First episodes of virologically-confirmed cases of COVID-19 of any severity

PROTECTION IN AGE GROUP OF 18 TO 60

Hospitalization and death 0 vs 6 (vaccine vs. placebo)

Moderate to severe 77%

Any severity 53%
The HERALD Study: Geographically Diverse and Multi-Variant

- Latin America: ~75% of study population
- Europe: ~25% of study population

The HERALD Study

- ~40,000 study participants
  - ~35,000 age 18 to 60
  - ~5,000 > age of 60

10 Countries
The HERALD Study: Sequencing Efforts Define Basis for Efficacy Calculation

Day 1
First dose 12µg

Day 29
Second dose 12µg

Day 43
Case Collection

15 days post second dose

228 adjudicated cases

Europe: 54 cases
LATAM: 174 cases

18 to 60: 207 cases
> Age 60: 21 cases

Europe: 49 cases
LATAM: 155 cases

18 to 60: 187 cases
> Age 60: 17 cases

204 adjudicated sequenced cases
COVID-19 Reality: Variants of Concern Spreading in Europe and Latin America

**EUROPE**
- Alpha (B.1.1.7, 501Y.V1)
- Beta (B.1.351, 501Y.V2)
- Gamma (P.1, 501Y.V3)
- Delta (B.1.617.2)
- Lambda (C.37)
- Other incl. original strain

**SOUTH AMERICA**
- Alpha (B.1.1.7 / 501Y.V1)
- Beta (B.1.351, 501Y.V2)
- Gamma (P.1, 501Y.V3)
- Delta (B.1.617.2)
- Lambda (C.37)
- Other incl. original strain

*As of June 25, source: [www.nextstrain.org](http://www.nextstrain.org) / South America- or Europe-focused sub-sampling*
HERALD Study: Variant Diversity Defines Basis for Efficacy in Final Analysis

CureVac │ Final Analysis Data Webcast

**LATIN AMERICA**
- B.1.621 (Colombia) ~19%
- Lambda ~28%
- Gamma ~23%
- Alpha ~13%
- Wild type ~4%
- Other ~13%
- 155 adjudicated cases (~76%)

**EUROPE**
- B.1.621 (Colombia) ~14%
- Gamma ~18%
- Alpha ~32%
- Lambda ~21%
- Delta ~1%
- Other ~11%
- Wild type ~3%
- 49 adjudicated cases (~24%)

**TOTAL**
- B.1.621 (Colombia) ~14%
- Gamma ~18%
- Alpha ~32%
- Lambda ~21%
- Delta ~1%
- Other ~11%
- Wild type ~3%
- 204 adjudicated cases

**15 different COVID-19 variants**

155 adjudicated cases (~76%)
49 adjudicated cases (~24%)
HERALD Study: Variant Diversity in Overall Study Reflect New COVID-19 Reality

Europe

- 110 adjudicated + non-adjudicated cases

Latin America

- 478 adjudicated + non-adjudicated cases
- 29 virus strains overall

Number of cases

- Belgium
- Germany
- Spain
- Netherlands
- Panama
- Mexico
- Colombia
- Argentina
- Peru

Virus strains:
- B.1 (wild type)
- B.1.1 (wild type)
- B.1.351 (Beta)
- P.1 (Gamma)
- B.1.617.2 (Delta)
- B.1.429 (Epsilon)
- C.37 (Lambda)
- P.2 (Zeta)
- B.1.621 (Colombia)
- B.1.1.519 (Mexico)
- N.5
- P.1.2
- A.2.5
- B.1.111
- B.1.520
- B.1.621
- B.1.160
- B.1.177
- B.1.177.43
- B.1.1.348
- B.1.1.318
- B.1.177.73
- C.11
- C.35
- C.36
- B.1.1.7.53
- B.1.236
**IN THE AGE GROUP OF 18 TO 60**

**100%**  
(0 vaccine vs. 6 placebo)  
**PROTECTION AGAINST HOSPITALIZATION OR DEATH**

**77%**  
(9 vaccine vs. 36 placebo)  
**PROTECTION AGAINST MODERATE TO SEVERE DISEASE**

**53%**  
(71 vaccine vs. 136 placebo)  
**OVERALL VACCINE EFFICACY**

**48%**  
**PRIMARY EFFICACY ENDPOINT**

**IN ALL AGE GROUPS**
### Balanced Trends for Efficacy Across Variants of Concern and Interest

**Efficacy by Strain Against Any Severity**  
*(Age Group of 18 to 60)*

<table>
<thead>
<tr>
<th>Variant</th>
<th>CVnCoV</th>
<th>Placebo</th>
<th>VE</th>
<th>LLCI</th>
<th>ULCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.621 (Colombia)</td>
<td>11</td>
<td>17</td>
<td>42</td>
<td>-25</td>
<td>73</td>
</tr>
<tr>
<td>Other</td>
<td>7</td>
<td>13</td>
<td>51</td>
<td>-24</td>
<td>80</td>
</tr>
<tr>
<td>Gamma (P.1)</td>
<td>9</td>
<td>26</td>
<td>67</td>
<td>30</td>
<td>85</td>
</tr>
<tr>
<td>Lambda (C.37)</td>
<td>13</td>
<td>26</td>
<td>53</td>
<td>8</td>
<td>76</td>
</tr>
<tr>
<td>Alpha (B.1.1.7)</td>
<td>20</td>
<td>42</td>
<td>55</td>
<td>24</td>
<td>74</td>
</tr>
</tbody>
</table>

VE: Vaccine efficacy; LLCI: Lower limit confidence interval; ULCI: Upper limit confidence interval
# Reactogenicity Data on First 2,000 Vaccinated Trial Participants

## SYSTEMIC SYMPTOMS

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Vaccination 1</th>
<th>Vaccination 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## LOCAL SYMPTOMS

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Vaccination 1</th>
<th>Vaccination 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swelling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Redness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Percentage of Participants**

- Grade 1
- Grade 2
- Grade 3
The HERALD Study: Key Messages

1. Favorable CVnCoV **efficacy profile** established in predefined age group of **18 to 60**

2. In 18 to 60 age group, **77%** protection against **moderate/severe** disease and **full protection** against **hospitalization/death**

3. Efficacies calculated in view of the **combined** influence of **15 different variants**

4. In 18 to 60 age group, balanced and robust **efficacy trends per strain** shown in the range of **42%** (B.1.621) to **67%** (Gamma)

5. Favorable **safety profile** in line with other mRNA vaccines further confirms safe applicability of CVnCoV

6. Full commitment to **continue regulatory submission** pathway; ongoing dialogue with the EMA within the rolling submission review process
Thank you for your attention